Found 16 articles for: "hilary baldwin"
Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Participants With Moderate-to-Severe Acne: The Patient Journey
November 2024 | Volume 23 | Issue 11 | Case Reports | 1017 | Copyright © November 2024
Introduction: Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is the only fixed-dose, triple-combination formulation approved for acne treatmen...
Read MoreClindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Male and Female Acne: Phase 3 Analysis
October 2024 | Volume 23 | Issue 10 | Original Article | 873 | Copyright © October 2024
Background: Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) is the only fixed-dose triple-combination treatment approved for acne. This post hoc analys...
Read MoreA Cosmetic Regimen Formulated to Address the Multi-Modal Pathogenesis of Rosacea Demonstrates Efficacy for Treating Facial Redness and Skin's Appearance
September 2024 | Volume 23 | Issue 9 | Original Article | 757 | Copyright © September 2024
Background: The treatment of rosacea is complicated as there are multiple pathogenic factors in play resulting in a myriad of clinical signs and symptoms including facial redness...
Read MoreTriple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne in Adult and Pediatric Participants
June 2024 | Volume 23 | Issue 6 | Original Article | 394 | Copyright © June 2024
Background: Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) is the first fixed-dose triple-combination approved for the treatment of acne. This...
Read MoreGoing Beyond Ceramides in Moisturizers: The Role of Natural Moisturizing Factors
June 2024 | Volume 23 | Issue 6 | Original Article | 466 | Copyright © June 2024
Xerosis is experienced by almost everyone at some time in their lives and the foundation of management of dry skin (both consumer- and healthcare professional--directed) rests on the use of moist...
Read MoreEarly and Sustained Acne Lesion Reductions With Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel
March 2024 | Volume 23 | Issue 3 | Original Article | 125 | Copyright © March 2024
Background: A once-daily, three-pronged approach using an antibiotic, antibacterial, and retinoid may provide faster acne improvement versus monotherapy or dual-combination produ...
Read MoreUnmet Needs in the Management of Acne Vulgaris: A Consensus Statement
June 2023 | Volume 22 | Issue 6 | Original Article | 582 | Copyright © June 2023
Acne vulgaris is the most common skin condition in the US, affecting up to 50 million Americans. The American Academy of Dermatology (AAD) guidelines on acne treatment were developed to provide r...
Read MoreSixty Years of Benzoyl Peroxide Use in Dermatology
January 2023 | Volume 22 | Issue 1 | Original Article | 54 | Copyright © January 2023
Background: Benzoyl peroxide (BPO) has been used extensively in industry and health care for more than a century and has been approved for the treatment of acne for over 60 years. Recently, BPO receiv...
Read MoreTretinoin Review With Newer Formulations: Providing Effective and Tolerable Solutions in Clinical Practice
January 2023 | Volume 22 | Issue 1 | Original Article | 35 | Copyright © January 2023
Topical tretinoin has historically been limited by poor tolerability and molecular instability. Research advances have enhanced its efficacy and tolerability, along with reducing oxidation and photode...
Read MoreTazarotene 0.045% Lotion for Females With Acne: Analysis of Two Adult Age Groups
June 2022 | Volume 21 | Issue 6 | Original Article | 587 | Copyright © June 2022
Background: Females aged ≥25 years may have acne with different etiology, presentation, burden, and treatment response than females 18–24 years. This post hoc analysis invest...
Read MoreUpdate on Facial Erythema in Rosacea
August 2021 | Volume 20 | Issue 8 | Original Article | 861 | Copyright © August 2021
Dermatologists are cognizant of the multiple clinical manifestations of rosacea, particularly persistent facial erythema, which has been deemed to be the most prevalent diagnostic feature and often po...
Read MoreManagement of Truncal Acne With Oral Sarecycline: Pooled Results from Two Phase-3 Clinical Trials
June 2021 | Volume 20 | Issue 6 | Original Article | 634 | Copyright © June 2021
Background: Acne vulgaris is a common skin disease that affects the face, chest, and back. While truncal acne is present in at least 50% of patients, clinical studies have focused pre...
Read MoreRationale for Use of Combination Therapy in Rosacea
October 2020 | Volume 19 | Issue 10 | Original Article | 929 | Copyright © October 2020
Background: Rosacea is a chronic skin condition characterized by primary and secondary manifestations affecting the centrofacial skin. The primary diagnostic phenotypes for rosacea ar...
Read MoreOnce-Daily Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Sex
August 2020 | Volume 19 | Issue 8 | Original Article | 777 | Copyright © August 2020
Background: Two identical phase 3 randomized, double-blind, vehicle-controlled, 12-week studies (NCT03168321 and NCT03168334) demonstrated the efficacy and safety of tazarotene 0.045%...
Read MoreImpact of Female Acne on Patterns of Health Care Resource Utilization
February 2015 | Volume 14 | Issue 2 | Original Article | 140 | Copyright © February 2015
BACKGROUND: Limited data are available on acne treatment patterns in females through their adult years.
OBJECTIVE: The purpose of this analysis was to evaluate health care resource utilization (H...
Read MorePipeline Previews
June 2013 | Volume 12 | Issue 6 | Features | 718 | Copyright © June 2013
Pipeline Previews brings to you information on the newest drugs and medical products as they become available to the dermatologic community. This department may include additional information from th...
Read MoreMedia and other results for: "hilary baldwin"
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
